Two 90Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy

Molecular Pharmaceutics

Volumn 8, Issue 2, 2011, Pages 591-599

  Liu, Zhaofei ^a   Shi, Jiyun ^a   Jia, Bing ^a   Yu, Zilin ^a   Liu, Yan ^a   Zhao, Huiyun ^a   Li, Fang ^b   Tian, Jie ^c   Chen, Xiaoyuan ^d   Liu, Shuang ^e   Wang, Fan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c INSTITUTE OF AUTOMATION   (China)

^d NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

90Y; Arg Gly Asp (RGD); integrin v 3; radionuclide therapy; tumor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3 PROLYLARGINYLGLYCYLASPARTIC ACID 2; ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID 4; INDIUM 111; UNCLASSIFIED DRUG; YTTRIUM 90; ARGINYL-GLYCYL-ASPARTIC ACID; INDIUM; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM; VITRONECTIN RECEPTOR; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIMERIZATION; DRUG ANTAGONISM; DRUG SCREENING; ENZYME SPECIFICITY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MAXIMUM TOLERATED DOSE; METABOLISM; NEOPLASM; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; DIMERIZATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INDIUM RADIOISOTOPES; INTEGRIN ALPHAVBETA3; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; OLIGOPEPTIDES; RADIOPHARMACEUTICALS; SUBSTRATE SPECIFICITY; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 79953834541     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100403y     Document Type: Article

References (26)

1. Kumar, C. C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets 2003, 4 (2), 123-31. (Pubitemid 36553584)
2. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 2008, 49 (Suppl. 2), 113S-28S.
3. Cai, W.; Niu, G.; Chen, X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des. 2008, 14 (28), 2943-73.
4. 3 expression in man. Clin. Cancer Res. 2006, 12 (13), 3942-9.
5. 18F]Galacto-RGD. PLoS Med. 2005, 2 (3), e70.
6. 18F-AH111585 in breast cancer patients. J. Nucl. Med. 2008, 49 (6), 879-86.
7. Janssen, M. L.; Oyen, W. J.; Dijkgraaf, I.; Massuger, L. F.; Frielink, C.; Edwards, D. S.; Rajopadhye, M.; Boonstra, H.; Corstens, F. H.; Boerman, O. C. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 2002, 62 (21), 6146-51.
8. Yoshimoto, M.; Ogawa, K.; Washiyama, K.; Shikano, N.; Mori, H.; Amano, R.; Kawai, K. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int. J. Cancer 2008, 123 (3), 709-15.
9. Haubner, R.; Decristoforo, C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front. Biosci. 2009, 14, 872-86.
10. Liu, S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)- targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem. 2009, 20 (12), 2199-213.
11. 64Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 2005, 46 (10), 1707-18.
12. 4 linkers. Eur. J. Nucl. Med. Mol. Imaging 2009, 36 (8), 1296-307.
13. 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J. Med. Chem. 2008, 51 (24), 7980-90.
14. 4 linkers. Bioconjugate Chem. 2009, 20 (4), 750-9.
15. 4 linkers. Mol. Pharmaceutics 2009, 6 (1), 231-45.
16. 3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Mol. Imaging 2010, 9 (1), 21-9.
17. 3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem. 2009, 20 (12), 2199-213.
18. 64Cu-labeled RGD-bombesin heterodimer. J. Nucl. Med. 2009, 50 (7), 1168-77.
19. Li, Z. B.; Cai, W.; Cao, Q.; Chen, K.; Wu, Z.; He, L.; Chen, X. 64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J. Nucl. Med. 2007, 48 (7), 1162-71.
20. Shi, J.; Kim, Y. S.; Chakraborty, S.; Zhou, Y.; Wang, F.; Liu, S. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers. Amino Acids 2010Epub ahead of print.
21. Chakraborty, S.; Shi, J.; Kim, Y. S.; Zhou, Y.; Jia, B.; Wang, F.; Liu, S. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent. Bioconjugate Chem. 2010, 21 (5), 969-78.
22. Janssen, M.; Oyen, W. J.; Massuger, L. F.; Frielink, C.; Dijkgraaf, I.; Edwards, D. S.; Radjopadhye, M.; Corstens, F. H.; Boerman, O. C. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm. 2002, 17 (6), 641-6.
23. Dijkgraaf, I.; Kruijtzer, J. A.; Liu, S.; Soede, A. C.; Oyen, W. J.; Corstens, F. H.; Liskamp, R. M.; Boerman, O. C. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 2007, 34 (2), 267-73.
24. Wu, Y.; Zhang, X.; Xiong, Z.; Cheng, Z.; Fisher, D. R.; Liu, S.; Gambhir, S. S.; Chen, X. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 2005, 46 (10), 1707-18.
25. 3 Expressed on both Tumor Cells and Neovasculature. Bioconjugate Chem. 2010, 21, 548-55.
26. 111In- labeled Abegrin™ in nude mouse models. Mol. Imaging Biol. 2011, 13 (1), 112-20.